ERBB2 and breast carcinoma: We assessed a panel of Her2+ breast cancer cells with respect to their relative sensitivities to treatment with Lapatinib, a small molecule inhibitor of Her2 and other epidermal growth factor receptor (EGFR) family members that is used in clinical practice.